序贯心理与药物治疗失眠障碍的有效性:一项随机临床试验
该序贯多分配随机试验纳入211名慢性失眠障碍成人,比较行为治疗或唑吡坦一线治疗后未缓解者接受药物或心理二线治疗的疗效。一线行为治疗与唑吡坦的应答率和缓解率相当;二线治疗中行为治疗转唑吡坦或认知治疗、唑吡坦转曲唑酮可显著提高缓解率,共病精神障碍者应答/缓解率较低但特定序贯方案更优。
要点
- 行为治疗与唑吡坦一线治疗失眠的应答率和缓解率无显著差异。
- 一线未缓解者加用二线治疗可提高应答率,行为治疗转唑吡坦或认知治疗显著。
- 共病焦虑或心境障碍者应答/缓解率较低,但特定序贯方案仍可改善结局。
核心结论
- 行为治疗与唑吡坦作为一线治疗失眠的应答率和缓解率相当。
- 初始治疗未缓解者加用二线治疗可带来额外获益。
研究设计与样本
- 序贯多分配随机试验,纳入211名慢性失眠障碍成人,其中74名共病焦虑或心境障碍。
- 患者先接受行为治疗(n=104)或唑吡坦(n=107),未缓解者接受二线药物或心理治疗。
主要发现
- 一线行为治疗与唑吡坦的应答率加权百分比分别为45.5%和49.7%(OR 1.18,95%CI 0.60-2.33)。
- 一线行为治疗与唑吡坦的缓解率加权百分比分别为38.03%和30.3%(OR 1.41,95%CI 0.75-2.65)。
- 行为治疗转唑吡坦应答率从40.6%升至62.7%(OR 2.46,95%CI 1.14-5.30)。
- 行为治疗转认知治疗应答率从50.1%升至68.2%(OR 2.09,95%CI 1.01-4.35)。
- 行为治疗转唑吡坦缓解率从38.1%升至55.9%(OR 2.06,95%CI 1.04-4.11)。
关键数值与推荐
- 主要终点为失眠严重指数总分定义的应答率和缓解率。
- 唑吡坦转曲唑酮缓解率从31.4%升至49.4%(OR 2.13,95%CI 0.91-5.00)。
- 共病精神障碍者应答/缓解率较低,但行为治疗转认知治疗或唑吡坦转曲唑酮结局更优。
- 应答和缓解率维持至12个月随访。
临床怎么用
- 失眠初始治疗可选择行为治疗或唑吡坦,二者疗效相当。
- 初始治疗未缓解者应序贯加用二线治疗,如行为治疗转唑吡坦或认知治疗。
- 共病焦虑或心境障碍的失眠患者可考虑行为治疗转认知治疗或唑吡坦转曲唑酮。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite evidence of efficacious psychological and pharmacologic therapies for insomnia, there is little information about what first-line treatment should be and how best to proceed when initial treatment fails. OBJECTIVE: To evaluate the comparative efficacy of 4 treatment sequences involving psychological and medication therapies for insomnia and examine the moderating effect of psychiatric disorders on insomnia outcomes. DESIGN, SETTING, AND PARTICIPANTS: In a sequential multiple-assignment randomized trial, patients were assigned to first-stage therapy involving either behavioral therapy (BT; n = 104) or zolpidem (zolpidem; n = 107), and patients who did not remit received a second treatment involving either medication (zolpidem or trazodone) or psychological therapy (BT or cognitive therapy [CT]). The study took place at Institut Universitaire en Santé Mentale de Québec, Université Laval, Québec City, Québec, Canada, and at National Jewish Health, Denver, Colorado, and enrollment of patients took place from August 2012 through July 2017. MAIN OUTCOMES AND MEASURES: The primary end points were the treatment response and remission rates, defined by the Insomnia Severity Index total score. RESULTS: Patients included 211 adults (132 women; mean [SD] age, 45.6 [14.9] years) with a chronic insomnia disorder, including 74 patients with a comorbid anxiety or mood disorder. First-stage therapy with BT or zolpidem produced equivalent weighted percentages of responders (BT, 45.5%; zolpidem, 49.7%; OR, 1.18; 95% CI, 0.60-2.33) and remitters (BT, 38.03%; zolpidem, 30.3%; OR, 1.41; 95% CI, 0.75-2.65). Second-stage therapy produced significant increases in responders for the 2 conditions, starting with BT (BT to zolpidem, 40.6% to 62.7%; OR, 2.46; 95% CI, 1.14-5.30; BT to CT, 50.1% to 68.2%; OR, 2.09; 95% CI, 1.01-4.35) but no significant change following zolpidem treatment. Significant increase in percentage of remitters was observed in 2 of 4 therapy sequences (BT to zolpidem, 38.1% to 55.9%; OR, 2.06; 95% CI, 1.04-4.11; zolpidem to trazodone, 31.4% to 49.4%; OR, 2.13; 95% CI, 0.91-5.00). Although response/remission rates were lower among patients with psychiatric comorbidity, treatment sequences that involved BT followed by CT or zolpidem followed by trazodone yielded better outcomes for patients with comorbid insomnia. Response and remission rates were well sustained through the 12-month follow-up. CONCLUSIONS AND RELEVANCE: Behavioral therapy and zolpidem medication produced equivalent response and remission rates. Adding a second treatment produced an added value for those whose insomnia failed to remit with initial therapies. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01651442.
引用
- Morin CM, Edinger JD, Beaulieu-Bonneau S, et al. Effectiveness of Sequential Psychological and Medication Therapies for Insomnia Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2020. PMID: 32639561. doi:10.1001/jamapsychiatry.2020.1767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。